ConductScience.org, home

Paper40284530

Thymoquinone Enhances Doxorubicin Efficacy via RAS/RAF Pathway Modulation in Ovarian Adenocarcinoma.

Toprak V and 5 others. Pharmaceutics, 2025. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. Thymoquinone Enhances Doxorubicin Efficacy via RAS/RAF Pathway Modulation in Ovarian Adenocarcinoma. Papers, record 40284530. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40284530

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Thymoquinone Enhances Doxorubicin Efficacy via RAS/RAF Pathway Modulation in Ovarian Adenocarcinoma.
PubMed
Journal
Pharmaceutics
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
2.12, provisional
iCite
Revised in PubMed
2025-04-28
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Toprak VVeysel
2Özdemir İİlhan
3Öztürk ŞŞamil
4Yanar OOrhan
5Kizildemir YZYusuf Ziya
6Tuncer MCMehmet Cudihttps://orcid.org/0000-0001-7317-5467

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134484227Hallmarks of Cancers: Primary Antibody Deficiency Versus Other Inborn Errors of Immunity.Front Immunol2021https://conductscience.org/library/papers/34484227PubMed
223744360Redox cycling of endogenous copper by thymoquinone leads to ROS-mediated DNA breakage and consequent cell death: putative anticancer mechanism of antioxidants.Cell Death Dis2013https://conductscience.org/library/papers/23744360PubMed
335437842Suppressive effects of thymoquinone on the initiation stage of diethylnitrosamine hepatocarcinogenesis in rats.J Biochem Mol Toxicol2022https://conductscience.org/library/papers/35437842PubMed
438248312Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer.Curr Issues Mol Biol2023https://conductscience.org/library/papers/38248312PubMed
532297580Thymoquinone, an Active Compound of Nigella sativa: Role in Prevention and Treatment of Cancer.Curr Pharm Biotechnol2020https://conductscience.org/library/papers/32297580PubMed
631099893Epithelial ovarian cancer: Evolution of management in the era of precision medicine.CA Cancer J Clin2019https://conductscience.org/library/papers/31099893PubMed
737909496Telomerase inhibitors TMPyP4 and thymoquinone decreased cell proliferation and induced cell death in the non-small cell lung cancer cell line LC-HK2, modifying the pattern of focal adhesion.Braz J Med Biol Res2023https://conductscience.org/library/papers/37909496PubMed
827798862Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies.Anticancer Res2016https://conductscience.org/library/papers/27798862PubMed
935011457Insights into the Protective Effects of Thymoquinone against Toxicities Induced by Chemotherapeutic Agents.Molecules2021https://conductscience.org/library/papers/35011457PubMed
1038087345Potential anticancer properties and mechanisms of thymoquinone in colorectal cancer.Cancer Cell Int2023https://conductscience.org/library/papers/38087345PubMed
1136432484Anticancer Effects of Thymoquinone through the Antioxidant Activity, Upregulation of Nrf2, and Downregulation of PD-L1 in Triple-Negative Breast Cancer Cells.Nutrients2022https://conductscience.org/library/papers/36432484PubMed
1238105263Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.Signal Transduct Target Ther2023https://conductscience.org/library/papers/38105263PubMed
1331433961Thymoquinone induces apoptosis of human epidermoid carcinoma A431 cells through ROS-mediated suppression of STAT3.Chem Biol Interact2019https://conductscience.org/library/papers/31433961PubMed
1435713779Programmed cell death detection methods: a systematic review and a categorical comparison.Apoptosis2022https://conductscience.org/library/papers/35713779PubMed
1533923474Thymoquinone, as a Novel Therapeutic Candidate of Cancers.Pharmaceuticals (Basel)2021https://conductscience.org/library/papers/33923474PubMed
1638510007Immune stimulatory effect of Nigella sativa in healthy animal models: A systematic review and meta-analysis.Heliyon2024https://conductscience.org/library/papers/38510007PubMed
1731885471Thymoquinone (2-Isoprpyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/anticancer agent: Chemistry and biological effects.Saudi Pharm J2019https://conductscience.org/library/papers/31885471PubMed
1832901987Thymoquinone inhibits the proliferation and invasion of esophageal cancer cells by disrupting the AKT/GSK-3β/Wnt signaling pathway via PTEN upregulation.Phytother Res2020https://conductscience.org/library/papers/32901987PubMed
1932798788Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer.Eur J Med Chem2020https://conductscience.org/library/papers/32798788PubMed
2028881699Thymoquinone, as an anticancer molecule: from basic research to clinical investigation.Oncotarget2017https://conductscience.org/library/papers/28881699PubMed

See all 29 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
42793131Epigallocatechin Gallate Modulates the Cellular Response to Doxorubicin in HeLa Cervical Cancer Cells.Biomolecules2026https://conductscience.org/library/papers/42793131PubMed
42792721Cytotoxic, Drug-Interaction, and Apoptosis-Associated Effects of β-Boswellic Acid and Doxorubicin in Murine 4T1 TNBC-like Cells.Biomedicines2026https://conductscience.org/library/papers/42792721PubMed
42792719Rosmarinic Acid Enhances Doxorubicin Activity in MDA-MB-231 Cells: Associations with Intracellular Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis.Biomedicines2026https://conductscience.org/library/papers/42792719PubMed
42653655Thymoquinone Potentiates Docetaxel-Induced Antitumor Activity with the Involvement of ROS and PI3K/AKT Pathway Modulation in Triple-Negative Breast Cancer Cells.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42653655PubMed
42351769Integrated Evaluation of the Synergistic Antitumor Effects of Thymoquinone and Docetaxel in Ovarian Cancer Cells: Apoptosis, Oxidative Stress, and 3D Spheroid Responses.Biomedicines2026https://conductscience.org/library/papers/42351769PubMed
42351676Synergistic Effects of Doxorubicin and Quercetin on ROS-Associated Apoptosis and EGFR/FOXP3 Modulation in OVCAR3 Cells.Biomedicines2026https://conductscience.org/library/papers/42351676PubMed
42196484A Functional Evaluation of Resveratrol-Paclitaxel Combination Reveals Enhanced Apoptotic Responses in HeLa Cells.Int J Mol Sci2026https://conductscience.org/library/papers/42196484PubMed
42075801Quercetin Sensitizes Retinoblastoma Cells to Mitomycin C Through Transcriptional Modulation of p53-Regulated Apoptotic Genes: A Preclinical Study.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42075801PubMed
41749873Synergistic Antitumor Activity of Curcumin and the PARP1 Inhibitor PJ34 in Platinum-Sensitive and Resistant Ovarian Cancer Cells.Cancers (Basel)2026https://conductscience.org/library/papers/41749873PubMed
41596149Molecular Insights into the Synergistic Anticancer and Oxidative Stress-Modulating Activity of Quercetin and Gemcitabine.Antioxidants (Basel)2026https://conductscience.org/library/papers/41596149PubMed
41020906Synergistic Induction of Apoptosis by Boswellic Acid and Cisplatin in A549 Lung Cancer Cells Through NF-κB Modulation and p53 Pathway Activation.Curr Issues Mol Biol2025https://conductscience.org/library/papers/41020906PubMed
41010990Combined Hesperidin and Gemcitabine Therapy Modulates Apoptosis and Angiogenesis Pathways in ISHIKAWA Human Endometrial Adenocarcinoma Cells.Medicina (Kaunas)2025https://conductscience.org/library/papers/41010990PubMed
40870392PI3K/Akt1 Pathway Suppression by Quercetin-Doxorubicin Combination in Osteosarcoma Cell Line (MG-63 Cells).Medicina (Kaunas)2025https://conductscience.org/library/papers/40870392PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BAX581PubTator's text mininghttps://conductscience.org/library/genes/581NCBI Gene
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
ZHX222882PubTator's text mininghttps://conductscience.org/library/genes/22882NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40284530

GET https://conductscience.org/api/papers/v1/40284530/references?page=2